NEUROP, INC.

Basic Information

58 Edgewood Road
ATLANTA, GA, 30303-

Company Profile

n/a

Additional Details

Field Value
DUNS: 148559987
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics

    Amount: $219,338.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

    Amount: $2,675,001.00

    DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a str ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators

    Amount: $691,992.00

    DESCRIPTION (provided by applicant): Schizophrenia is a chronic neurological disorder that affects approximately 1% of the world population and causes gt 60 billion dollars of direct and indirect soc ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

    Amount: $3,159,861.00

    DESCRIPTION provided by applicant Cerebral ischemia is a major cause of death and long term disability with high accompanying social and medical costs Approximately Americans suffer a str ...

    SBIR Phase II 2012 Department of Health and Human Services National Institutes of Health
  5. Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

    Amount: $299,541.00

    DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a str ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Evaluation of pH Dependent Neuroprotectants in SAH Model

    Amount: $144,137.00

    DESCRIPTION (provided by applicant): The goal of this STTR project is to determine if NeurOp's pH-sensitive NMDAR antagonists improve functional recovery and reduce neuronal injury in a validated muri ...

    STTR Phase I 2008 Department of Health and Human Services
  7. Neuroprotection of pH Sensitive NMDAR Antagonists in Cardiopulmonary Bypass Surge

    Amount: $125,788.00

    DESCRIPTION (provided by applicant): Heart operations involving the use of cardiopulmonary bypass (CPB) are among the most common surgical procedures in the world, with over 500,000 performed in the U ...

    SBIR Phase I 2007 Department of Health and Human Services
  8. pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection

    Amount: $1,403,580.00

    DESCRIPTION (provided by applicant): Ischemic injury of the brain is a major cause of death and morbidity, and often causes long term disability. NMDA receptor (NMDAR) blockers, particularly targeting ...

    SBIR Phase II 2006 Department of Health and Human Services
  9. In vivo proof of concept:pH-dependent neuroprotection

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Neurodegeneration accompanying stroke and certain types of seizure is a significant problem that has been refractory to treatment despite intensive investigation i ...

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government